Discover this Nature Communications paper describing how LentiFlash® RNA particles can be safely used to correct efficiently the Hutchinson-Gilford progeria syndrome mutation and improve skin pheno...
We are delighted to have met you at the ASGCT in Washington D.C, on May 16-19. The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting, celebrating its 25th year in 2022, is the...
€15M, 3-year financing agreement with TECHLIFE CAPITAL and ELAIA PARTNERS
We are pleased to announce that our team will be attending the 28th ESGCT Annual Meeting to be held virtually October 19-22, 2021
Flash Therapeutics va doubler ses capacités de production de lots cliniques d’ici 2022 et amplifier la fabrication de lots à grande échelle à partir de 2023
Flash Therapeutics to double its clinical batch production capacity by 2022 and expand to large-scale batch manufacturing starting 2023